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A substantial proportion of patients with adult-onset
diabetes share features of both type 1 diabetes (T1D)
and type 2 diabetes (T2D). These individuals, at diagno-
sis, clinically resemble T2D patients by not requiring
insulin treatment, yet they have immunogenetic markers
associated with T1D. Such a slowly evolving form of
autoimmune diabetes, described as latent autoimmune
diabetesof adults (LADA), accounts for 2–12%of all patients
with adult-onset diabetes, though they show consider-
able variability according to their demographics and
mode of ascertainment. While therapeutic strategies
aim for metabolic control and preservation of residual
insulin secretory capacity, endotype heterogeneity within
LADA implies a personalized approach to treatment.
Faced with a paucity of large-scale clinical trials in LADA,
an expert panel reviewed data and delineated one ther-
apeutic approach. Building on the 2020 AmericanDiabetes
Association (ADA)/European Association for the Study of
Diabetes (EASD) consensus for T2D and heterogeneity
within autoimmune diabetes, we propose “deviations”
for LADA from those guidelines. Within LADA, C-peptide
values, proxy for b-cell function, drive therapeutic deci-
sions. Three broad categories of random C-peptide levels
were introduced by the panel: 1) C-peptide levels <0.3
nmol/L: a multiple-insulin regimen recommended as for
T1D; 2) C-peptide values ‡0.3 and £0.7 nmol/L: defined by
the panel as a “gray area” in which a modified ADA/EASD
algorithm for T2D is recommended; consider insulin in
combination with other therapies to modulate b-cell
failure and limit diabetic complications; 3) C-peptide
values >0.7 nmol/L: suggests a modified ADA/EASD
algorithm as for T2D but allowing for the potentially
progressive nature of LADA by monitoring C-peptide
to adjust treatment. The panel concluded by advising
general screening for LADA in newly diagnosed non–
insulin-requiring diabetes and, importantly, that large
randomized clinical trials are warranted.
Both type 1 diabetes (T1D) and type 2 diabetes (T2D) are
complex heterogeneous diseases with a highly variable
clinical course given that not all patients fit into the
current binary classification. A substantial subgroup of
patients, mostly with onset in adulthood, share several
characteristics of both T1D and T2D as described over
30 years ago (1–3). These patients are considered to have
a slowly progressive form of autoimmune diabetes with
serum immune markers of T1D but not requiring insulin at
diagnosis. Such patients identified as having latent auto-
immune diabetes of adults (LADA) account for 2–12% of
all patients with diabetes, with considerable variability
according to ethnicity, type of autoantibody used for
screening (most often autoantibody against glutamic acid
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decarboxylase [GADA]), and method of ascertainment
(primary care shows lower rates than secondary care)
(4–12). LADA is part of the autoimmune diabetes spec-
trum, encapsulated by the term T1D, but with marked
differences in endophenotypes across the spectrum (13).
LADA, also called type 1.5 diabetes, is a global phenom-
enon with an estimated 6 million people with this condi-
tion in China (10). Higher disease rates are reported in
Northern Europe and regions of China (7–14%) compared
with African American and Hispanic individuals (14–16).
Notwithstanding the widespread recognition of LADA,
there are no guidelines for its management. An interna-
tional group of experts convened a meeting to address this
issue. The following report consists of three sections: 1)
identifying subjects with LADA, 2) reviewing current ther-
apeutic options, and 3) presenting the group’s proposal for
management of LADA.
LADA is a well-recognized form of diabetes; however,
there are no guidelines for its management. The panel
concluded that there is a need for defining a strategy for
the management of LADA.
Identifying Subjects With LADA
Adult-onset diabetes (.30 years at diagnosis), presence of
diabetes-associated autoantibodies, and absence of insulin
requirement for at least 6 months after diagnosis are the
key current diagnostic criteria for LADA (Table 1). None of
these criteria are categorical; given that LADA is clinically
and metabolically a hybrid of T1D and T2D, it is challeng-
ing to define categorical immunogenetic and phenotypic
features (17–20). Notably, a similar type of slowly pro-
gressive form of autoimmune diabetes can also be found in
young-onset cases called latent autoimmune diabetes in
the young (LADY) (21), reflecting a wide latitude for the
variable age at diagnosis. Few studies compare LADA with
T1D presenting at similar ages (9,22). Andersen et al. (22)
showed that even those LADA patients with higher GADA
levels (highest quartile) had better insulin secretion and
higher BMI than those with adult-onset (.35 years) T1D,
whereas in a cross-sectional study, GADA-positive patients
started on insulin between 1 and 6 months post-diagnosis
(considered T1D) could not be distinguished phenotypically
frompatients with LADA (9). Furthermore, GADA positivity
may be transient before clinical diabetes develops (23).
Importantly, considering the heterogeneity of LADA, for
the clinician it is not possible to be certain that any given
patient does or does not have LADA without estimating
diabetes-associated autoantibodies. However, some anam-
nestic and clinical features may help the clinician identify
likely LADA patients, including age,50 years, family and/
or personal autoimmunity, BMI ,25 kg/m2, and acute
symptoms at onset (24). A clinical diagnostic model has
recently been developed on cross-sectional data to iden-
tify need for insulin and low C-peptide within 3 years
(considered T1D) or not (considered T2D) based on five
parameters including age at diagnosis, BMI, GADA and
tyrosine phosphatase (IA-2) autoantibodies (IA-2A), and
T1D genetic risk score (25). This model provides an area
under the receiver operating characteristic curve (ROC
AUC) of 0.90 (clinical features only) to 0.97 (all five
parameters) with low prediction error, but it only applies
to European-origin patients aged between 18 and 50 years
at diagnosis and, being cross-sectional, is not predictive.
Characteristics of LADA
i) Phenotypical Features
Data obtained from all major studies including the UK
Prospective Diabetes Study (UKPDS) (4) and the Botnia
study (5) show that the autoantibody frequency (GADA) in
patients diagnosed with T2D is higher in younger patients
compared with older patients (e.g., in UKPDS from 34%
when aged 25–34 years to 7% in older patients aged 55–65
years). On average, patients with LADA, compared with
those with antibody-negative T2D, are younger at diabetes
diagnosis with lower BMI and have a personal or family
history of autoimmune diseases. Metabolic syndrome tends
to have a similar or higher frequency in LADA compared
with adult-onset T1D (5,22,26), but compared with auto-
antibody-negative T2Dpatients, LADApatients show a lower
frequency, with lower HOMA of insulin resistance index
(HOMA-IR) and blood pressure (BP) and less diabetic
dyslipidemia (5,9). However, there is considerable hetero-
geneity, with some patients having a T1D phenotype (with-
out metabolic syndrome) while others are indistinguishable
from T2D (with metabolic syndrome) (22,27). Although
patients with LADA have less major cardiovascular risk
factors, i.e., they are leaner, with better lipid and BP profiles,
there is no difference in cardiovascular outcomes in them
compared with T2D patients after adjustment for tradi-
tional cardiovascular risk factors (28,29).
In a post hoc analysis of UKPDS, LADA subjects at
diabetes onset have a lower risk of microvascular compli-
cations that becomes higher secondary to worse glycemic
control compared with T2D subjects. This suggests that
the optimization of glycemia may prevent later risk of
these complications (30).
C-peptide levels decrease more slowly in LADA than in
T1D, and this marker may be used to stage LADA patients
according to their residual b-cell function and progression
Table 1—Broad characteristics of LADA*
c Age .30 years**
c Family/personal history of autoimmunity
c Reduced frequency of metabolic syndrome compared with
T2D—lower HOMA, lower BMI, lower blood pressure, and
normal HDL compared with T2D
c No disease-specific difference in cardiovascular outcomes
between these patients and those with T2D
c C-peptide levels decrease more slowly than in T1D
c Positivity for GADA as the most sensitive marker; other
autoantibodies less frequent (ICA, IA-2A, ZnT8A, and
tetraspanin 7 autoantibodies)
c Non–insulin requiring at onset of diabetes
*None of these features categorically define LADA. **Limited data
on older patients with higher probability of T1D in younger patients.
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toward insulin requirement (27,31–33). The risk of pro-
gression to insulin deficiency is variable, depending on age
at diagnosis, autoantibody level, and presence of multiple
islet autoantibodies (4,5,9,10,34).
ii) Autoantibodies
GADA is considered the most sensitive marker of LADA as
it is the predominant autoantibody, whether in Europe or
China, and in primary or in secondary care; e.g., the Action
LADA study showed that approximately 90% of LADA
subjects with diabetes-associated autoantibodies are GADA
positive (9,15). GADA can be detected by commercially
available radioimunoassays as well as ELISA.
GADA specificity has improved from 94% to 99% from
2010 to 2018 according to the international islet autoan-
tibody standardization program (35).
Patients with high GADA levels tend toward a T1D-like
phenotype with lower BMI and lower prevalence of met-
abolic syndrome (7,22,26). In addition, UKPDS and all
other studies found that high GADA levels were associated
with an increased risk of insulin requirement (4,34).
Importantly, a fraction of autoantibody-positive cases
could have false positive autoantibodies either through
assay variation or limited predictive power for insulin
dependence (36), reducing the predictive value of any given
autoantibody. Increasing the autoantibody assay specificity
and enriching the population under study for LADA will
increase the positive predictive value.
It follows that some patients with GADA will have T2D
and should be treated as such, a dilemma circumvented, in
part, by placing more emphasis on C-peptide levels.
Other autoantibodies target different IA-2 epitopes
(IA-2A), insulin (IAA), the islet-specific zinc transporter
isoform 8 (ZnT8A), and tetraspanin 7, while other GADA
epitopes are less frequent in LADA (15,16,37–41). A
recent study (40) found that individuals with LADA,
positive for N-terminally truncated GADA, have a clinical
phenotype more similar to classical T1D and a higher
odds ratio for early progression to insulin therapy compared
with patients positive for the full-length GADA. This may
have important practical implications for prediction of risk
for insulin therapy. The autoantibody that recognizes the
IA-2IC epitope is most utilized for the diagnosis of young-
onset T1D at diagnosis and identifies LADA with a sensi-
tivity and specificity of approximately 30% and 100%,
respectively. Autoantibodies against the IA-2(256–760) frag-
ment were shown to be a reliable marker of LADA with
a sensitivity and specificity of 40% and 97%, respectively (37).
Diabetes-associated autoantibody positivity is predictive
for progression both to non–insulin-dependent diabetes
(23,42,43) and especially to future insulin dependency after
the diagnosis of diabetes, e.g., UKPDS found at least 50% of
LADA patients required insulin treatment 6 years post-
diagnosis (4,25). However, not all patients in UKPDS and in
other studies required insulin, even after 10 years from
diagnosis. An important feature of LADA is the increased
risk of other organ-specific autoantibodies and autoimmune
diseases. GADA are predictive of thyroid autoimmunity
(7,36,44,45), while IA-2 autoantibodies confer a high risk
of celiac disease–associated autoimmunity in China (15).
Moreover, in LADA, high GADA levels are strongly asso-
ciated with thyroid autoimmunity and inversely related to
the serum cytokine profile (44,45).
iii) Genetic Susceptibility
The shared genetic susceptibility of LADA and T1D includes
polymorphisms within the HLA DQB1 and DRB1 genes
and within the insulin and protein-tyrosine-phosphatase
nonreceptor 22 (PTPN22) genes (19); all these gene poly-
morphisms and the Src homology 2-B (SH2B3) gene were
identified in a recent large well-powered genome-wide
association study (46). On the other hand, in relatively
small studies, LADA was associated with the strongest T2D
variant transcription factor 7–like 2 (TCF7L2) (47–49),
especially in overweight cases (50), but not in the genome-
wide association study or in a Chinese study, the latter
potentially due to ethnic differences (46,51). Moreover,
class I genes (HLA-A and HLA-B) are not associated with
LADA, whereas they are strongly associated with child-
hood-onset T1D (52). Application of gene risk scores may
assist stratification of rates of progression to insulin de-
pendency in patients with diabetes-associated autoanti-
bodies and help identify cases likely to have false positive
autoantibodies (25).
Treatment of Patients With LADA: Overview of Current
Approaches
By definition, LADA patients have functioning b-cells at
diagnosis indicating that it is imperative to implement
therapeutic strategies targeted to improve metabolic con-
trol but also to preserve the insulin-secreting capacity (53).
To make a proposal for treatment of LADA, the panel
reviewed current clinical trial data and reiterated
the conclusions of the Cochrane Review regarding lack
of good-quality, large-scale, controlled trials with long-
term follow-up (54). As mentioned earlier, the criteria
used to define LADA are shown in Table 1. Of note, our
proposal only applies to patients who initially were con-
sidered not to need insulin.
Hypoglycemic Agents
Insulin Sensitizers (Metformin, Thiazolidinediones). The
majority of LADA patients are clinically diagnosed as
having T2D and treated initially with metformin before
they are identified as having LADA. The panel concluded
that although there is little evidence for the use of met-
formin, there is no evidence against its use. Metformin can
increase insulin sensitivity in T1D (55) without evidence
that it could improve long-term glycemic control; in ad-
dition, it might reduce weight, LDL cholesterol levels, and
the risk of atherosclerosis progression (56). Results from
ongoing clinical trials, investigating the effects in LADA
patients of monotherapy/adjunct metformin on metabolic
control, b-cell function, and tolerability, will provide more
evidence on the precise role of metformin.
diabetes.diabetesjournals.org Buzzetti and Associates 2039
In a small study (n 5 23 patients), thiazolidinediones
(TZD), when combined with insulin, preserved b-cell func-
tion in LADA, although the study needs to be replicated (57).
In a four-arm, randomized trial performed in 54 Chinese
subjects, LADA patients were assigned to either sulfonyl-
urea (SU) (n 5 14) or rosiglitazone (n 5 15) therapy if
GADA was ,175 units/mL and fasting C-peptide was
.0.3 nmol/L. While fasting C-peptide was not different
between the two groups, C-peptide levels post–oral glucose
and delta C-peptide were higher with rosiglitazone as
compared with the SU group after 18 months and up to
36 months (P , 0.05 for all comparisons) (58).
Data Quality Assessment




The panel concluded that there is limited evidence sup-
porting the use of metformin and few studies using TZD,
so the efficacy of both compounds appears inconclusive.
For TZD, the potential risk of atypical bone fractures,
macular edema, and weight gain could be a limitation to
the use of these compounds.
Insulin. While therapy with insulin is essential in all cases
with undetectable C-peptide, patients diagnosed with LADA
have, by definition, residual b-cell function and, in general,
slow progression toward insulin dependency. A major
question is whether insulin therapy should be the initial
treatment for LADA (59). There are no data from large
randomized, controlled trials with sufficient length of
follow-up to draw a conclusion. A Japanese randomized
trial comparing insulin (n 5 30) with an SU (n 5 30) over
a 5-year period showed significantly better integrated C‐
peptide response with insulin. Thus, in the insulin-treated
group, progression to insulin-requiring diabetes was lower
compared with SU (P 5 0.003) (60). On the other hand,
Thunander et al. (61) concluded that early insulin treat-
ment for LADA did not lead to preservation of b-cell
function (n 5 37), although it was well tolerated and
resulted in better metabolic control (in the control group
but not in the insulin-treated group, HbA1c increased signif-
icantly at 36 months compared with baseline [P 5 0.006],
while C-peptide decline was progressive, irrespective of age,
sex, BMI, HbA1c values, and autoantibody levels). Inter-
estingly, UKPDS found that 11.6% of patients were
autoantibody-positive and that they tended to require
insulin treatment sooner, irrespective of other allocated
therapy (4,62). The data available, although limited,
indicate that insulin intervention is effective for meta-
bolic control in LADA patients. However, it remains to be
established whether insulin should be administered at an
early stage of the clinical disease or whether it is the
optimal therapy regardless of the stage of the disease
process. Further studies are needed to clarify the impact
of insulin therapy and the optimum time for intervention.
Data Quality Assessment




The panel concluded that insulin intervention is effective
and safe for LADA patients; however, it still remains to be
established whether insulin should be administered in the
early stages of LADA, especially when substantial residual
b-cell function is present.
Sulfonylureas. As with previous agents discussed, there is
limited evidence to suggest the efficacy of SU in subjects
with LADA (19). In a multicenter, randomized, nonblinded
clinical study, Japanese patients with LADA, randomized
to insulin or glibenclamide (n 5 30 in each group), were
followed for up to 5 years. During follow-up, the SU group
had worse metabolic control and a more rapid decline
in C-peptide level compared with the group treated with
insulin (P 5 0.005) (63). More recently, a post hoc
exploratory analysis of a small subgroup of LADA patients
(n 5 38), enrolled in a randomized, controlled trial com-
paring glimepiride and linagliptin (n 5 21 linagliptin, n 5
17 glimepiride) at 28 weeks as add-on therapy to metfor-
min in T2D, revealed that despite similar glycemic efficacy,
fasting C-peptide at 28, 52, and 104 weeks decreased in
patients treated with glimepiride. Conversely, an increase
in C-peptide level was observed in those subjects treated
with linagliptin; the difference between groups was sig-
nificant at 28 and 58 weeks (P, 0.01 for all comparisons)
(64). As previously described, in a four-arm pilot, random-
ized, controlled trial performed in 54 Chinese subjects with
LADA, comparison of 3-year follow-up data between sub-
jects treated with SU (n 5 14) showed a lower delta
C-peptide as well as C-peptide after 2-h 75-g glucose load
compared with patients treated with rosiglitazone (n5 15)
(P , 0.05 for all comparisons), with no differences in
glycemic control (58). Overall, the current data are incon-
clusive, but it cannot be excluded that treatment of LADA
with SU results in a decreased insulin secretion. SU are not
therefore recommended for the treatment of LADA, nor are
they generally recommended as first-line therapy for T2D.
Data Quality Assessment




The panel concluded that sulfonylureas are not recom-
mended for the treatment of LADA, as deterioration of
b-cell function as a consequence of this treatment cannot
be ruled out.
Dipeptidyl Peptidase 4 Inhibitors. Small clinical trials
with dipeptidyl peptidase 4 inhibitors (DPP‐4i) in patients
with LADA suggest that this class of hypoglycemic agents
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might improve glycemic control and preserve b‐cell func-
tion with a good safety profile compared with placebo,
glimepiride, and pioglitazone (64–66). In a post hoc anal-
ysis of pooled data from five randomized, placebo-
controlled studies (n 5 2,709), saxagliptin improved
b-cell function as assessed by HOMA2 of b-cell function
and postprandial C-peptide from baseline in both GADA-
positive (n5 98) and GADA-negative subjects (n5 1,849)
(67). A recent study (68) compared the outcome of glu-
cagon-stimulated C-peptide tests after 21-month treat-
ment with either insulin or sitagliptin in GADA-positive
LADA patients (n5 64) without any clinical indication for
insulin treatment less than 3 years from diagnosis. The
metabolic control during intervention did not differ between
the two treatment arms, and post-interventionb-cell function
was similar in the insulin- and sitagliptin-treated patients. Of
note, the stimulated C-peptide response deteriorated signif-
icantly more in the group with high GADA level compared
with the group with low level regardless of the treatment.
Another small study (n 5 30) found that sitagliptin, as an
add-on treatment to insulin, had a beneficial effect on
C-peptide decline compared with insulin alone (65).
Moreover, a recent trial evaluated the effect of saxa-
gliptin in combination with vitamin D3 in subjects with
LADA with promising results (69). Although these stud-
ies have several limitations (i.e., post hoc analyses, small
sample size, short periods of follow-up, interstudy het-
erogeneity), DPP-4i agents represent a potential thera-
peutic alternative for effective management of LADA.
Data Quality Assessment




The panel concluded that DPP-4i may improve glycemic
control in LADA patients with a good safety profile. Larger
randomized studies are warranted to prove that DPP-4i
might preserve C-peptide secretion.
Sodium–Glucose Cotransporter 2 Inhibitors. Sodium–
glucose cotransporter 2 inhibitors (SGLT2i) improve
glycemic control without hypoglycemia and are currently
used for the management of T2D. Although no interven-
tional studies have been conducted in LADA patients,
international, multicenter, randomized clinical trials in
over 5,000 T1D patients confirm the efficacy and safety of
adding SGLT2i to existing insulin regimens (70–77). One
SGLT2i, dapagliflozin, has been recently approved by the
European Medicines Agency for use in adults with T1D
with BMI of at least 27 kg/m2 who failed to achieve
adequate glycemic control despite optimal insulin ther-
apy. However, in the U.S., the use of SGLT2i in T1D still
remains off-label. The approval was based on data from
phase III DEPICT clinical program (70). SGLT inhibition
confers additional benefits in terms of HbA1c reduction,
reduced glucose variability, small reduction in weight, and
reduced total daily insulin doses without increasing the
risk of hypoglycemia. However, there is an increased risk
of ketoacidosis, often not associated with hyperglycemia,
especially in patients not overweight (BMI ,27 kg/m2).
This feature is of special importance in those LADA
patients with medium to low C-peptide levels and not on
insulin, considering their increased risk of developing
insulin deficiency. Treatment with SGLT2i might mask
the signs of progression to insulin deficiency (often present-
ing as postprandial hyperglycemia) and yet increase the risk
of ketoacidosis; therefore, patients should be advised to
monitor for ketosis, i.e., measure ketonemia and keto-
nuria regularly, even daily, as recommended (78), and to
discontinue SGLT2i prior to scheduling surgical proce-
dures or exposure to metabolically stressful conditions
associatedwith potential symptoms or signs of ketoacidosis.
Data Quality Assessment




The panel concluded that the approved use of SGLT2i in
both T2D and selected T1D patients, in particular those
overweight, suggests that they may be promising agents in
LADA. However, no studies have been performed in LADA
and attention should be paid to ketoacidosis in patients with
medium to low C-peptide.
Glucagon‐Like Peptide 1 Receptor Agonists. Glucagon‐
like peptide 1 receptor agonists (GLP‐1RA) reduce hyper-
glycemia (with low rates of hypoglycemia), reduce and
maintain weight control, and may suppress appetite, re-
duce food intake, and slow gastric emptying. A post hoc
analysis of pooled data from three randomized phase III
trials (AWARD-2, -4, and -5; patients with GADA assess-
ment) indicated that dulaglutide is effective in reducing
HbA1c in LADA patients. Dulaglutide treatment resulted in
a comparable decrease in HbA1c values in GADA-negative
(21.09%) and GADA-positive (20.94%) patients at 1 year
post-diagnosis, and it appears to be slightly more effective
in LADA patients with low autoantibody levels compared
with those with high autoantibody levels (79). However, as
expected, there was a reduced glycemic response to GLP-1RA
analogs (exenatide/liraglutide) in a small patient group
(n 5 19) with diabetes-associated autoantibodies and low
fasting C-peptide levels (#0.25 nmol/L) (80). Large-scale,
prospective, randomized trials with long-term follow-up
are required to confirm the efficacy of GLP‐1RA in pre-
serving metabolic control and delaying progression to
insulin dependence in LADA.
Data Quality Assessment
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The panel concluded that GLP-1RA have shown beneficial
results in terms of improving metabolic control in LADA
patients unless C-peptide levels are very low. These drugs
are approved in T2D and in insulin-treated patients, but
more evidence is required in patients with LADA.
Immune Intervention
There is only one immune intervention study in LADA
patients. Alum-formulated recombinant GADA (GAD-alum)
was used in a small phase 2 study that was placebo-controlled
with dose escalation in GADA-positive non–insulin-
requiring patients (n 5 47), who received subcutaneous
injections of GAD-alum in different doses (81). The pri-
mary outcome was safety as assessed by neurological tests,
medication use, and b-cell function evaluated over 5 years,
representing the end of the trial (82). No severe study-
related adverse events occurred during the 5-year follow-
up, and active treatment was not associated with increased
risk of starting insulin treatment compared with placebo.
After 5 years, fasting C-peptide levels declined in the
placebo group compared with the two highest dose in-
tervention groups. The authors concluded that in this
small study, the primary outcome of safety was achieved,
with evidence of a beneficial effect on b-cell function. A
more extensive trial is required before such treatment can
be recommended and is currently under way.
Data Quality Assessment




The panel concluded that current data on immune in-
tervention in LADA are very limited, and more extensive
phase 2 studies are required before drawing any conclusions.
Lifestyle Modifications
LADA is associated with factors that favor insulin resis-
tance and T2D, including low birth weight, overweight/
obesity, physical inactivity, smoking, and consumption of
sweetened drinks (12). The role of obesity and insulin
resistance as risk factors for LADA is abundantly docu-
mented (83). It may therefore be possible to treat LADA by
a combination of lifestyle changes much as is done in T2D.
Among these, medically assisted weight loss if necessary,
increased physical activity, and cessation of smoking
should be promoted. Thus, intervention studies examining
the role of lifestyle factors in the development of LADA are
necessary, as our current knowledge is hampered because
the small number of studies were conducted exclusively in
Scandinavian populations (83).
Quality Assessment




The panel concluded that lifestyle modifications are im-
portant in treatment of T2D. Intervention studies ex-
amining the role of weight reduction and physical activity
in the development of LADA are required.
Proposal for Management of LADA
Diagnostic Challenges in LADA
The panel agreed that to effectively identify patients
affected by LADA, all newly diagnosed T2D patients should
be screened for GADA positivity (immune marker with the
highest sensitivity) to allow for a rapid diagnosis and
implementation of an appropriate therapy and follow-up
of progressing b-cell failure. This approach may be costly,
but the one-off cost of GADA measurement (currently
around V5 or $6) is justified.
As they become available, new cost-effective bioassays
detecting autoantibodies targeting other islet autoantigens
(in addition to GADA) should be considered to diagnose
LADA. If, however, economic issues represent an obstacle,
at least one of the following clinical factors should be sought
to select patients in whom to measure GADA: family
history of T1D or autoimmune diseases (84), normal/slightly
Figure 1—Algorithm for LADA diagnostic pathway based on autoantibody screening and C-peptide levels at diagnosis (to be used when
financial restriction does not apply). **Consider also pancreatitis or monogenic diabetes.
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overweight BMI (,27), young age at onset (,60 years), and
poor metabolic control. If patients are GADA positive, they
are managed according to Fig. 1. If there is a strong suspicion
of LADA in a GADA-negative individual, other islet autoanti-
bodies (e.g., ICA or IA-2A, ZnT8A) should be assayed. GADA-
negative (autoantibody-negative), likely T2D, patients are
managed according to Fig. 1. Although elevated levels of
GADA have been associated with a greater risk of insulin
requirement compared with low levels, GADA levels cannot
be used in clinical practice for therapeutic choice because it
is difficult to set a threshold to discriminate between high
and low levels, bioassays are semiquantitative, and there is
variation in GADA levels between different laboratories.
The panel recommends measurement of serum (plasma)
C-peptide levels as a proxy for insulin secretion in islet-cell
related autoantibody–positive patients (85). In sampling
for C-peptide evaluation, the concomitant measurement of
blood glucose levels should be done to ensure that it is
between 80 and 180mg/dL to avoid the effect of abnormally
low or high glucose values. C-peptide can be measured in
samples collected at fasting, random time points, or post-
prandially. The data on fasting C-peptide is supported by
two recent prospective studies (in Europe and China) with
results consistent with our current proposal (67,86) The
mixed meal tolerance test has been considered the gold
standard to measure postprandial C-peptide, but it cannot
be performed routinely in clinical settings. However, many
clinical laboratories have applied the mixed meal tolerance
test values (87) for C-peptide measured 2 h after a random
meal, although this has not been yet standardized.
C-peptide assays are commercially available, inexpensive,
and widely accessible (Fig. 1).
By definition, LADA patients have detectable C-peptide
at diagnosis, which, in general, decreases more slowly than
in T1D patients (depending on the genetic characteristics)
(88) and more rapidly than in T2D patients. Similarly, in
case of treatment failure, C-peptide measurement should
be repeated to identify progression to insulin deficiency
and the need for insulin treatment.
C-peptide measurement should drive the decision-making
process for the choice of LADA treatment. Three broad
categories of C-peptide levels were suggested by the panel:
 C-peptide levels <0.3 nmol/L: a multiple-insulin reg-
imen is recommended. If this occurs at diagnosis, then
patients can be considered to have T1D and approved
national/international guidelines for T1D can be fol-
lowed thereafter.
 C-peptide levels ‡0.3 and £0.7 nmol/L: defined by
the panel as the “gray area” where a modified American
Diabetes Association (ADA)/European Association for
the Study of Diabetes (EASD) algorithm for T2D is
recommended (Figs. 2 and 3). The modification consists
of avoiding the use of hypoglycemic drugs that may have
an effect in deteriorating b-cell function.
Insulin in combination with other therapies to control/
prevent diabetic complications should be considered.
The advantages/disadvantages and even dangers of
Figure 2—Algorithm for glucose-loweringmedications in LADA patients with C-peptide,0.3 mmol/L or with C-peptide$0.3 and#0.7 nmol/L.
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate; HF, heart failure.
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using certain classes of agents need to be taken into
account when prescribed alone. Follow-up of patients
in this C-peptide category should take place at least every 6
months. Note that many adult-onset T1D patients have
C-peptide levels in this range at diagnosis, so patients
with marked hyperglycemia may need to be started on
insulin with frequent review.
 C-peptide levels >0.7 nmol/L: suggests using a slightly
modified ADA/EASD algorithm for T2D, notably the only
difference being that LADA patients should be followed
with repeated C-peptide measurements if there is a de-
terioration of glucose control; some of these cases will have
false positive autoantibodies and therefore be true T2D.
Personalized Therapy for LADA and the ADA/EASD
Guidelines
The overall objective of a personalized approach for the
management of LADA is to achieve good metabolic control
and preserve b-cell function.
The clinical guidelines for the management of hyper-
glycemia in T2D do not take into account the diverse
metabolic phenotypes of LADA. The 2020 ADA/EASD
guidelines for T2D do not suggest any specific treatment
for LADA, which constitutes a significant fraction of
patients with adult-onset diabetes (89). The panel felt it
was important to provide recommendations for the man-
agement of these patients in clinical practice. Our proposal
for LADA is defined on the basis of deviations/variations
from the ADA/EASD algorithm for T2D driven by the
measurement of C-peptide for evaluating b-cell function.
Each “deviation” for LADA patients from the ADA/EASD
T2D guidelines is outlined (Figs. 1–3). The use of metfor-
min and/or insulin elicited much discussion among the
panel, but it was concluded that they both have a role.
Importantly, for personalized therapy, the first step is to
establish the fundamental disease characteristics before
deciding on a therapeutic path; we appreciate that, likely as
not, estimating C-peptide and diabetes-associated autoan-
tibodies will be done infrequently in the average clinic.
Metformin is recommended in GADA-positive patients
(in particular those who are obese) who cannot be “con-
trolled” with diet alone. The addition of other hypogly-
cemic agents such as incretin-based therapy (GLP-1RA or
DPP-4i), TZD, and SGLT2i may confer some additional
advantages, e.g., weight loss, cardiovascular/renal protection
(Figs. 2 and 3).
Key Knowledge Gaps/Future Perspectives
Patients identified as having LADA account up to 12% of
all patients with diabetes attending clinics.
Our proposal embodies an attempt at making both
general and specific recommendations for LADA, on the
basis of its descriptive and functional features. These
recommendations offer a personalized, multidimensional,
and integrated guide for the physician to facilitate the
management of LADA.
The identification and treatment of LADA poses sig-
nificant challenges for the physician. The faculty outlined
some key points for future action, including a) screening
for LADA, b) personalized medicine, c) need for more
randomized controlled comparative trials with hypoglycemic
agents, d) further investigation of immune therapy, e) large-
scale long-term studies in different patient populations, f)
quality of life/lifestyle issues, g) studies including patients of
different ethnic origin, h) nature/quality of autoantibody
assays (GADA, IA-2, etc.), and i) cost-benefits balance of
measuring GADA autoantibodies and serum C-peptide.
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